Dear Pharmacist,

IMBRUVICA^®, being assigned a maximum fair price (MFP), intends to adjust the wholesale acquisition cost (WAC) to equal the MFP when MFP comes into effect January 1, 2026.¹ As a result, the manufacturer refund (difference between WAC and MFP) will be zero.

BACKGROUND

The assignment of an MFP for select drugs as part of the IRA will change the drug reimbursement process. If WAC is higher than the MFP, dispensing entities (DEs) will have to be refunded the difference between WAC and MFP by the drug manufacturer.

AbbVie is committed to minimizing access barriers

For more information about the IMBRUVICA^® MFP please email ImbruvicaIRA@Abbvie.com.

For more information on MTF enrollment and the Medicare Drug Price Negotiation Program, please review helpful resources for pharmacies and DEs directly from the CMS website.

CMS may be contacted by phone at: 877-MTF-4HLP (877-683-4457) or email at: MFPMedicareTransactionFacilitator@cms.hhs.gov

It is important to note that CMS guidance is ongoing, and that many unknowns still exist. Information communicated on the website is subject to change in the future.

CMS = Centers for Medicare & Medicaid Services; IRA = Inflation Reduction Act; MTF = Medicare Transaction Facilitator.

Reference: 1. Medicare Drug Price Negotiation Program: negotiated prices for initial price applicability year 2026. CMS. August 2024. Accessed August 27, 2025. https://www.cms.gov/newsroom/fact-sheets/medicare-drug-price-negotiation-program-negotiated-prices-initial-price-applicability-year-2026

This content is sponsored by Pharmacyclics and Johnson & Johnson, and ION Oncology Practice Network has not independently reviewed or verified the information provided by Pharmacyclics and Johnson & Johnson.

This email was sent to karleigh.bard-marsh@cencora.com because you have an account with or are a valued partner of Cencora Specialty GPOs | ION Oncology Practice Network. If you no longer wish to receive these types of emails, please click here to unsubscribe or update your email preferences.